At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
UpSwinG: Real World Study on TKI Activity in Uncommon Mutations and Sequencing Giotrif®
In Brief
An observational study evaluating Afatinib (Gi(l)otrif®), Erlotinib (Tarceva®), and 2 other interventions for Non-squamous, Non-Small Cell Lung Cancer. Completed, enrolled 462 participants across 1 site.
Detailed Summary
Non-interventional, multi-country, multi-centre cohort study based on existing data from medical records (paper or electronic) or electronic health records of patients with advanced NSCLC harbouring EGFR mutations and treated with an EGFR-TKI
Study Details
Timeline
Interventions
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
As first line therapy.
In the case the T790M resistance mutation was developed (second line therapy).